Sabin Institute acquires rights to develop vaccines for Ebola and Marburg viruses
The nonprofit Sabin Vaccine Institute is taking over development of vaccines to protect against two species of Ebola and a related virus, Marburg, acquiring the rights from GSK, the two entities announced Tuesday.
The transfer of the rights for the vaccines will put back into development a vaccine that GSK had shelved after the West African Ebola outbreak of 2014-2016. No money is changing hands; GSK is giving the rights to the institute.
